NCT05721950View on ClinicalTrials.gov

A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)

Active, not recruitingOBSERVATIONAL
Enrollment

154

Participants

Timeline

Start Date

January 17, 2024

Primary Completion Date

March 20, 2028

Study Completion Date

December 30, 2028

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
DRUG

Brigatinib

Brigatinib Tablets

Trial Locations (1)

200433

Department of Oncology, Shanghai pulmonary hospital, Shanghai

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT05721950 - A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter